Showing 5 of 48 posts
March 5, 2018 | Blogs
CAR T-Cell Combos: Potentially the Next Big Thing in Solid Tumors, Yet Pricing ‘Sticker Shock’ is not the Only Hurdle to be Overcome
After years of anticipation, CAR-Ts (chimeric antigen receptor–T-cells) finally made the transition from being promising future therapies, to breakthrough marketed products in 2017. CBPartners' Cell and Gene Therapy Center of Excellence explores the challenges that CAR-T combination therapies face.
November 22, 2017 | Blogs
November 6, 2017 | Blogs
In an unprecedented move, the UK's National Institute for Health and Care Excellence (NICE) recently recommended NHS funding of GSK's gene therapy STRIMVELIS™ for an ultra-orphan immunodeficiency disorder ADA-SCID1 – also dubbed the “Bubble Baby Syndrome” priced at EUR 594,000. Given NICE’s resistance to such high per-patient therapy costs, CBPartners investigates how GSK was able to defend the value positioning of the STRIMVELIS™ to NICE.
October 16, 2017 | Blogs
October is breast cancer awareness month, and In light of our recent PDx (PD1 / PD-L1) analysis, CBPartners decided to take a closer look at the potential for these paradigm-shifting therapies to make a difference for patients diagnosed with breast cancer.
October 9, 2017 | Blogs
As a class, manufacturers of PDxs (PD1s / PD-L1) are enjoying great success when it comes to marketing authorisation, with four of the five brands achieving multiple FDA and EMA approvals. CBPartners takes a closer look at the successes and failures in this highly competitive class of drugs.